{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:15:24Z","timestamp":1775711724102,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008306"],"award-info":[{"award-number":["2020YFC2008306"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.seizure.2023.10.004","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:47:16Z","timestamp":1696639636000},"page":"107-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["UGT1A polymorphism rs4148324 associated with topiramate plasma concentration to dose ratio in children with epilepsy"],"prefix":"10.1016","volume":"116","author":[{"given":"Shifeng","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.seizure.2023.10.004_bib0001","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure Medications for Adults With Epilepsy: A Review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.seizure.2023.10.004_bib0002","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: a review of its use in the treatment of epilepsy","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2023.10.004_bib0003","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pharmthera.2006.07.005","article-title":"Novel anticonvulsant drugs","volume":"113","author":"Stefan","year":"2007","journal-title":"Pharmacol Ther"},{"issue":"3-4","key":"10.1016\/j.seizure.2023.10.004_bib0004","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejps.2013.07.008","article-title":"Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling","volume":"50","author":"Jovanovi\u0107","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"S1","key":"10.1016\/j.seizure.2023.10.004_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1528-1157.2000.tb02174.x","article-title":"Clinical pharmacology of topiramate: a review","volume":"41","author":"Garnett","year":"2000","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"10.1016\/j.seizure.2023.10.004_bib0007","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0008","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1080\/21655979.2022.2036916","article-title":"Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population","volume":"13","author":"Zhao","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.seizure.2023.10.004_bib0009","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jpba.2013.08.024","article-title":"Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS\/MS method determines its turnover number and correlates with its glucuronidation activities","volume":"88","author":"Xu","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","article-title":"Pharmacogenomics of human UDP-glucuronosyltransferase enzymes","volume":"3","author":"Guillemette","year":"2003","journal-title":"Pharmacogenom J"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0011","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17425255.2019.1575361","article-title":"Pharmacokinetic considerations for anti-epileptic drugs in children","volume":"15","author":"Verrotti","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.seizure.2023.10.004_bib0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0000000000000185","article-title":"A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus","volume":"26","author":"Li","year":"2016","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"10.1016\/j.seizure.2023.10.004_bib0013","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/FPC.0b013e3283117d67","article-title":"Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression","volume":"18","author":"Kwan","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.seizure.2023.10.004_bib0014","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1037\/a0015700","article-title":"A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers","volume":"17","author":"Ray","year":"2009","journal-title":"Exp Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2023.10.004_bib0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0016","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.seizure.2023.10.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115437","article-title":"Simultaneous determination of 24 antiepileptic drugs and their active metabolites in human plasma by UHPLC-MS\/MS","volume":"232","author":"Jiang","year":"2023","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.seizure.2023.10.004_bib0018","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1073\/pnas.98.2.581","article-title":"High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"98","author":"Buetow","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.seizure.2023.10.004_bib0019","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","article-title":"The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"114","author":"Sun","year":"2015","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.seizure.2023.10.004_bib0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1755-5949.2012.00321.x","article-title":"Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up","volume":"18","author":"Zhou","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0021","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/ph14030204","article-title":"Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters","volume":"14","author":"Iannaccone","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.seizure.2023.10.004_bib0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy","volume":"117","author":"Wang","year":"2015","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0023","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2023.10.004_bib0024","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2016.02.002","article-title":"Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis","volume":"37","author":"Bae","year":"2016","journal-title":"Seizure"},{"issue":"2-3","key":"10.1016\/j.seizure.2023.10.004_bib0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.eplepsyres.2010.12.004","article-title":"Topiramate pharmacokinetics in infants and young children: contribution of population analysis","volume":"93","author":"Bouillon-Pichault","year":"2011","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.seizure.2023.10.004_bib0026","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1248\/bpb.33.1176","article-title":"A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy","volume":"33","author":"Vovk","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"10.1016\/j.seizure.2023.10.004_bib0027","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eplepsyres.2014.03.011","article-title":"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment","volume":"108","author":"Manitpisitkul","year":"2014","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2023.10.004_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/nu11010090","article-title":"Genome-Wide Association Study (GWAS) on Bilirubin Concentrations in Subjects with Metabolic Syndrome: Sex-Specific GWAS Analysis and Gene-Diet Interactions in a Mediterranean Population","volume":"11","author":"Coltell","year":"2019","journal-title":"Nutrients"},{"issue":"22","key":"10.1016\/j.seizure.2023.10.004_bib0029","doi-asserted-by":"crossref","first-page":"e925","DOI":"10.1097\/MD.0000000000000925","article-title":"Exome-Wide Association Study Identifies New Low-Frequency and Rare UGT1A1 Coding Variants and UGT1A6 Coding Variants Influencing Serum Bilirubin in Elderly Subjects: A Strobe Compliant Article","volume":"94","author":"Oussalah","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.seizure.2023.10.004_bib0030","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/pharmaceutics14102082","article-title":"Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain","volume":"14","author":"Bravo-G\u00f3mez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.seizure.2023.10.004_bib0031","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan","author":"Hulshof","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.seizure.2023.10.004_bib0032","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.clpt.6100019","article-title":"Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein","volume":"81","author":"de Jong","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"10.1016\/j.seizure.2023.10.004_bib0033","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2014.55.2307","article-title":"Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer","volume":"32","author":"Innocenti","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.seizure.2023.10.004_bib0034","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2013an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.seizure.2023.10.004_bib0035","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.23370","article-title":"UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma","volume":"112","author":"Liu","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.seizure.2023.10.004_bib0036","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FPC.0b013e328354026b","article-title":"Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)\u2087TAA and UGT1A4 L48V polymorphisms","volume":"22","author":"Erickson-Ridout","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.seizure.2023.10.004_bib0037","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hup.2308","article-title":"Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects","volume":"28","author":"Cabaleiro","year":"2013","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2023.10.004_bib0038","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2009.03363.x","article-title":"Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics","volume":"67","author":"Trontelj","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.seizure.2023.10.004_bib0039","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.seizure.2023.10.004_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.01.001","article-title":"Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin","volume":"198","author":"Schwertner","year":"2008","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.seizure.2023.10.004_bib0041","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2217\/pgs-2016-0063","article-title":"Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity","volume":"17","author":"Bins","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.seizure.2023.10.004_bib0042","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.seizure.2023.10.004_bib0043","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.seizure.2023.10.004_bib0044","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1515\/CCLM.2008.035","article-title":"Rare TA repeats in promoter TATA box of the UDP glucuronosyltranferase (UGT1A1) gene in Croatian subjects","volume":"46","author":"Nikolac","year":"2008","journal-title":"Clin Chem Lab Med"},{"issue":"18","key":"10.1016\/j.seizure.2023.10.004_bib0045","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.seizure.2023.10.004_bib0046","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1096\/fasebj.3.6.2649403","article-title":"Promoter specificity and modulation of RNA polymerase II transcription","volume":"3","author":"Saltzman","year":"1989","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.seizure.2023.10.004_bib0047","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2014.03.047","article-title":"Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences","volume":"146","author":"Erlinger","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123002698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123002698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T07:55:55Z","timestamp":1740815755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123002698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":47,"alternative-id":["S1059131123002698"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.10.004","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UGT1A polymorphism rs4148324 associated with topiramate plasma concentration to dose ratio in children with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}